GLP-1 receptor agonists and weight-loss strategies for individuals with obesity and hip or knee osteoarthritis: a scoping review.

IF 15.5 1区医学 Q1 SPORT SCIENCES

British Journal of Sports Medicine Pub Date : 2026-09-21 DOI:10.1136/bjsports-2025-111225

Conor J McCann, Nick D Clement, Andrew Murray, Ronan Kearney, Sharon Madigan, Christopher W Gee, Phil Walmsley, Scott Morrison, Swati Chopra, Andrew J Hall

{"title":"GLP-1 receptor agonists and weight-loss strategies for individuals with obesity and hip or knee osteoarthritis: a scoping review.","authors":"Conor J McCann, Nick D Clement, Andrew Murray, Ronan Kearney, Sharon Madigan, Christopher W Gee, Phil Walmsley, Scott Morrison, Swati Chopra, Andrew J Hall","doi":"10.1136/bjsports-2025-111225","DOIUrl":null,"url":null,"abstract":"Objective: To map current strategies for weight loss in hip and knee osteoarthritis (OA), with emphasis on the emerging role of glucagon-like peptide-1 receptor agonists (GLP-1-RAs) as tools in achieving weight loss and impacting symptoms, disease progression and perioperative outcomes in individuals with obesity.Design: Scoping review conducted in accordance with the Preferred Reporting Items for Systematic Reviews and Meta-Analyses extension for Scoping Reviews (PRISMA-ScR) framework and methodological guidance from the Joanna Briggs Institute and Arksey and O'Malley.Data sources: PubMed, Web of Science, Directory of Open Access Journals, Scopus, ProQuest Central (1 January 2010 to 18 August 2025).Eligibility criteria: Included studies focused on adults (≥18 years) with obesity and hip or knee OA, examined weight-loss strategies (nutritional, physical activity, surgical or pharmacological) including GLP-1-RAs.Results: Of 199 included studies, 36 (18.1%) directly assessed GLP-1-RAs and of these, 14/36 (38.9%) reported original data. Evidence was heavily skewed towards knee OA, with limited hip-specific data. Descriptive analysis revealed a narrow geographical distribution of studies and a rapidly increasing focus on GLP-1-RAs; most studies involving GLP-1-RAs (29/36, 80.6%) were published between 2024 and 2025 and were of a low level of evidence (19/36, 52.8% level 5). Randomised and cohort data in knee OA indicate that GLP-1-RAs are associated with substantial weight loss, with accompanying improvements in pain/function and reduced progression to arthroplasty. In contrast, evidence in hip OA is sparse with weaker associations.Conclusion: GLP-1-RAs represent a promising adjunct for managing individuals with OA complicated by obesity. Until further evidence emerges, GLP-1-RAs should be integrated into supervised, multimodal musculoskeletal care rather than used as standalone weight-loss agents.","PeriodicalId":9276,"journal":{"name":"British Journal of Sports Medicine","volume":" ","pages":"1325-1338"},"PeriodicalIF":15.5000,"publicationDate":"2026-09-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"British Journal of Sports Medicine","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1136/bjsports-2025-111225","RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"SPORT SCIENCES","Score":null,"Total":0}

引用次数: 0

Abstract

Objective: To map current strategies for weight loss in hip and knee osteoarthritis (OA), with emphasis on the emerging role of glucagon-like peptide-1 receptor agonists (GLP-1-RAs) as tools in achieving weight loss and impacting symptoms, disease progression and perioperative outcomes in individuals with obesity.

Design: Scoping review conducted in accordance with the Preferred Reporting Items for Systematic Reviews and Meta-Analyses extension for Scoping Reviews (PRISMA-ScR) framework and methodological guidance from the Joanna Briggs Institute and Arksey and O'Malley.

Data sources: PubMed, Web of Science, Directory of Open Access Journals, Scopus, ProQuest Central (1 January 2010 to 18 August 2025).

Eligibility criteria: Included studies focused on adults (≥18 years) with obesity and hip or knee OA, examined weight-loss strategies (nutritional, physical activity, surgical or pharmacological) including GLP-1-RAs.

Results: Of 199 included studies, 36 (18.1%) directly assessed GLP-1-RAs and of these, 14/36 (38.9%) reported original data. Evidence was heavily skewed towards knee OA, with limited hip-specific data. Descriptive analysis revealed a narrow geographical distribution of studies and a rapidly increasing focus on GLP-1-RAs; most studies involving GLP-1-RAs (29/36, 80.6%) were published between 2024 and 2025 and were of a low level of evidence (19/36, 52.8% level 5). Randomised and cohort data in knee OA indicate that GLP-1-RAs are associated with substantial weight loss, with accompanying improvements in pain/function and reduced progression to arthroplasty. In contrast, evidence in hip OA is sparse with weaker associations.

Conclusion: GLP-1-RAs represent a promising adjunct for managing individuals with OA complicated by obesity. Until further evidence emerges, GLP-1-RAs should be integrated into supervised, multimodal musculoskeletal care rather than used as standalone weight-loss agents.

查看原文本刊更多论文

GLP-1受体激动剂和肥胖和髋关节或膝关节骨关节炎患者的减肥策略：范围综述

目的：绘制髋关节和膝关节骨关节炎（OA）的当前减肥策略，重点关注胰高血糖素样肽-1受体激动剂（GLP-1-RAs）作为实现减肥和影响肥胖患者症状、疾病进展和围手术期结局的工具的新作用。设计：根据系统评价和荟萃分析扩展范围评价的首选报告项目（PRISMA-ScR）框架和乔安娜布里格斯研究所和Arksey和O'Malley的方法指导进行范围评价。数据来源：PubMed， Web of Science, Open Access Journals Directory, Scopus, ProQuest Central（2010年1月1日至2025年8月18日）。入选标准：纳入了针对肥胖和髋关节或膝关节OA的成人（≥18岁）的研究，研究了包括GLP-1-RAs在内的减肥策略（营养、体育活动、手术或药物）。结果：199项纳入的研究中，36项（18.1%）直接评估了GLP-1-RAs，其中14/36（38.9%）报告了原始数据。证据严重偏向膝关节OA，髋关节特异性数据有限。描述性分析显示研究的地理分布狭窄，对GLP-1-RAs的关注迅速增加；大多数涉及GLP-1-RAs的研究（29/36,80.6%）发表于2024 - 2025年间，证据水平较低（19/36,52.8%,level 5）。膝关节OA的随机和队列数据表明，GLP-1-RAs与体重显著减轻、疼痛/功能改善和关节置换术进展减少相关。相比之下，髋部OA的证据较少，相关性较弱。结论：GLP-1-RAs是治疗OA合并肥胖患者的一种有希望的辅助手段。在进一步的证据出现之前，GLP-1-RAs应该整合到有监督的多模式肌肉骨骼护理中，而不是单独用作减肥药。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

British Journal of Sports Medicine 医学-运动科学

CiteScore

27.10

自引率

4.90%

发文量

217

审稿时长

3-8 weeks

期刊介绍： The British Journal of Sports Medicine (BJSM) is a dynamic platform that presents groundbreaking research, thought-provoking reviews, and meaningful discussions on sport and exercise medicine. Our focus encompasses various clinically-relevant aspects such as physiotherapy, physical therapy, and rehabilitation. With an aim to foster innovation, education, and knowledge translation, we strive to bridge the gap between research and practical implementation in the field. Our multi-media approach, including web, print, video, and audio resources, along with our active presence on social media, connects a global community of healthcare professionals dedicated to treating active individuals.